Cellnovo acquires commercial license for Artificial Pancreas Technology from Type Zero Technologies
in portfolio news
Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, and digital health company TypeZero Technologies, today announce the completion of a worldwide commercial license agreement for the integration and the commercialization of TypeZero’s Artificial Pancreas (AP) technology into Cellnovo’s mobile diabetes management systems.
The non - exclusive worldwide agreement allows Cellnovo to commercialize a Cellnovo - TypeZero product in the future. Integration efforts are currently underway with a product launch expected in 2018. No financial terms have been disclosed.